KD-496 is under clinical development by Nanjing KAEDI Biotech and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KD-496’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KD-496 is under development for the treatment of solid tumors, gastric cancer and pancreatic cancer. The therapeutic candidate is a fourth generation CAR-T cell therapy comprising T cells which are genetically engineered to express chimeric antigen receptor (CAR) by targeting cells expressing Claudin 18.2 (CLDN18.2) and NKG2DL. It is administered through parenteral route.
Nanjing KAEDI Biotech overview
Nanjing KAEDI Biotech., is a pharmaceutical company that develops new CAR, TCR and antibody drugs for the treatment of malignant tumors. The company is headquartered China.
For a complete picture of KD-496’s drug-specific PTSR and LoA scores, buy the report here.